Ankylosing Spondylitis Market Size, Top Share, Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Ankylosing Spondylitis Market Size Analysis

Global Ankylosing Spondylitis Market Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value
U.S.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    1. By Value
    2. TNF Inhibitors
      1. TNF Inhibitors By Value
    3. Humira
      1. Humira By Value
    4. Simponi
      1. Simponi By Value
    5. Remicade
      1. Remicade By Value
    6. Enbrel
      1. Enbrel By Value
    7. Cimzia
      1. Cimzia By Value
    8. Other TNF Inhibitors
      1. Other TNF Inhibitors By Value
  3. Other Drug Classes
    1. By Value
2. By Disease Stage
  1. Introduction
    1. Disease Stage By Value
  2. Early-Stage Ankylosing Spondylitis
    1. By Value
  3. Moderate Ankylosing Spondylitis
    1. By Value
  4. Severe / Advanced Ankylosing Spondylitis
    1. By Value
3. By Diagnostic Method
  1. Introduction
    1. Diagnostic Method By Value
  2. MRI
    1. By Value
  3. X-Ray Radiography
    1. By Value
  4. Blood Biomarkers (CRP/ESR)
    1. By Value
  5. HLA-B27 Genetic Testing
    1. By Value
  6. Digital Spine Monitoring Tools
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value
U.K.
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    1. By Value
    2. TNF Inhibitors
      1. TNF Inhibitors By Value
    3. Humira
      1. Humira By Value
    4. Simponi
      1. Simponi By Value
    5. Remicade
      1. Remicade By Value
    6. Enbrel
      1. Enbrel By Value
    7. Cimzia
      1. Cimzia By Value
    8. Other TNF Inhibitors
      1. Other TNF Inhibitors By Value
  3. Other Drug Classes
    1. By Value
2. By Disease Stage
  1. Introduction
    1. Disease Stage By Value
  2. Early-Stage Ankylosing Spondylitis
    1. By Value
  3. Moderate Ankylosing Spondylitis
    1. By Value
  4. Severe / Advanced Ankylosing Spondylitis
    1. By Value
3. By Diagnostic Method
  1. Introduction
    1. Diagnostic Method By Value
  2. MRI
    1. By Value
  3. X-Ray Radiography
    1. By Value
  4. Blood Biomarkers (CRP/ESR)
    1. By Value
  5. HLA-B27 Genetic Testing
    1. By Value
  6. Digital Spine Monitoring Tools
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value
China
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    1. By Value
    2. TNF Inhibitors
      1. TNF Inhibitors By Value
    3. Humira
      1. Humira By Value
    4. Simponi
      1. Simponi By Value
    5. Remicade
      1. Remicade By Value
    6. Enbrel
      1. Enbrel By Value
    7. Cimzia
      1. Cimzia By Value
    8. Other TNF Inhibitors
      1. Other TNF Inhibitors By Value
  3. Other Drug Classes
    1. By Value
2. By Disease Stage
  1. Introduction
    1. Disease Stage By Value
  2. Early-Stage Ankylosing Spondylitis
    1. By Value
  3. Moderate Ankylosing Spondylitis
    1. By Value
  4. Severe / Advanced Ankylosing Spondylitis
    1. By Value
3. By Diagnostic Method
  1. Introduction
    1. Diagnostic Method By Value
  2. MRI
    1. By Value
  3. X-Ray Radiography
    1. By Value
  4. Blood Biomarkers (CRP/ESR)
    1. By Value
  5. HLA-B27 Genetic Testing
    1. By Value
  6. Digital Spine Monitoring Tools
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value
UAE
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    1. By Value
    2. TNF Inhibitors
      1. TNF Inhibitors By Value
    3. Humira
      1. Humira By Value
    4. Simponi
      1. Simponi By Value
    5. Remicade
      1. Remicade By Value
    6. Enbrel
      1. Enbrel By Value
    7. Cimzia
      1. Cimzia By Value
    8. Other TNF Inhibitors
      1. Other TNF Inhibitors By Value
  3. Other Drug Classes
    1. By Value
2. By Disease Stage
  1. Introduction
    1. Disease Stage By Value
  2. Early-Stage Ankylosing Spondylitis
    1. By Value
  3. Moderate Ankylosing Spondylitis
    1. By Value
  4. Severe / Advanced Ankylosing Spondylitis
    1. By Value
3. By Diagnostic Method
  1. Introduction
    1. Diagnostic Method By Value
  2. MRI
    1. By Value
  3. X-Ray Radiography
    1. By Value
  4. Blood Biomarkers (CRP/ESR)
    1. By Value
  5. HLA-B27 Genetic Testing
    1. By Value
  6. Digital Spine Monitoring Tools
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Class
1. Introduction
  1. Drug Class By Value
2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
  1. By Value
  2. TNF Inhibitors
    1. TNF Inhibitors By Value
  3. Humira
    1. Humira By Value
  4. Simponi
    1. Simponi By Value
  5. Remicade
    1. Remicade By Value
  6. Enbrel
    1. Enbrel By Value
  7. Cimzia
    1. Cimzia By Value
  8. Other TNF Inhibitors
    1. Other TNF Inhibitors By Value
3. Other Drug Classes
  1. By Value
By Disease Stage
1. Introduction
  1. Disease Stage By Value
2. Early-Stage Ankylosing Spondylitis
  1. By Value
3. Moderate Ankylosing Spondylitis
  1. By Value
4. Severe / Advanced Ankylosing Spondylitis
  1. By Value
By Diagnostic Method
1. Introduction
  1. Diagnostic Method By Value
2. MRI
  1. By Value
3. X-Ray Radiography
  1. By Value
4. Blood Biomarkers (CRP/ESR)
  1. By Value
5. HLA-B27 Genetic Testing
  1. By Value
6. Digital Spine Monitoring Tools
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacy
  1. By Value
3. Retail Pharmacy
  1. By Value
4. Others
  1. By Value
Brazil
1. By Drug Class
  1. Introduction
    1. Drug Class By Value
  2. Non-Steroidal Anti-Inflammatory Drug (NSAID)
    1. By Value
    2. TNF Inhibitors
      1. TNF Inhibitors By Value
    3. Humira
      1. Humira By Value
    4. Simponi
      1. Simponi By Value
    5. Remicade
      1. Remicade By Value
    6. Enbrel
      1. Enbrel By Value
    7. Cimzia
      1. Cimzia By Value
    8. Other TNF Inhibitors
      1. Other TNF Inhibitors By Value
  3. Other Drug Classes
    1. By Value
2. By Disease Stage
  1. Introduction
    1. Disease Stage By Value
  2. Early-Stage Ankylosing Spondylitis
    1. By Value
  3. Moderate Ankylosing Spondylitis
    1. By Value
  4. Severe / Advanced Ankylosing Spondylitis
    1. By Value
3. By Diagnostic Method
  1. Introduction
    1. Diagnostic Method By Value
  2. MRI
    1. By Value
  3. X-Ray Radiography
    1. By Value
  4. Blood Biomarkers (CRP/ESR)
    1. By Value
  5. HLA-B27 Genetic Testing
    1. By Value
  6. Digital Spine Monitoring Tools
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacy
    1. By Value
  3. Retail Pharmacy
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Ankylosing Spondylitis Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

AbbVie Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Novartis Pharmaceuticals Corporation
UCB S.A.
Amgen Inc.
Pfizer Inc.
Eli Lilly and Company
Janssen-Cilag Limited
Merck & Co., Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
CELLTRION INC.
Samsung Bioepis
Reliance Life Sciences
Zydus Lifesciences Limited
Gilead Sciences, Inc.
Hoffmann-La Roche Ltd
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment